Aim To investigate the serum value of brain derived neurotrophic factor (BDNF), proteins S-100, NSE, IL-6 in normal pressure patients (NPH) compared to control (healthy) group and also a possible correlation with radiological findings in NPH patients. Methods Study patients were included during the period of 2020-2022. All NPH patients met the diagnostic criteria for probability of NPH. Control patients group included patients without known brain disorder, without clinical symptoms of NPH. Blood samples were taken before planned surgery for NPH. BDNF serum concentrations were assessed by a sensitive ELISA kit, and serum concentrations of S-100, NSE and IL-6 were assessed by using ECLIA technology for immunoassay detection. Results Among 15 patients who were included, seven NPH patients were compared to eight control patients. Non-significant decrease in BDNF serum concentrations, an increase of protein S-100 serum concentrations, a decrease of NSE serum concentrations, as well as an increase of IL-6 serum concentrations in NPH patients compared to healthy controls was found. Strong positive correlation between BNDF and Evans index was observed (p=0.0295). Conclusion We did not find a significant difference of BDNF, protein S-100, IL-6 and NSE between serum concentration in NPH and healthy patients. More future research is needed to find the role of BDNF in NPH patients.
Skalický P, Mládek A, Vlasák A, Lacy P, Beneš V, Bradáč O. Normal pressure hydrocephalus-an overview of pathophysiological mechanisms and diagnostic procedures. Vol. 43, Neurosurg Rev. 2020. p. 1451–64.
2.
Andersson J, Rosell M, Kockum K, Lilja-Lund O, Söderström L, Laurell K. Prevalence of idiopathic normal pressure hydrocephalus: a prospective, population-based study. Vol. 14:e0217705, PLoS One. 2019.
3.
Takeuchi J, Yajima K. Long-term 4 years follow-up study of 482 patients who underwent shunting for idiopathic normal pressure hydrocephalus - course of symptoms and shunt efficacy rates compared by age group. Vol. 59, Neurol Med Chir. 2019. p. 6.
4.
Santangelo R, Cecchetti G, Bernasconi MP, Cardamone R, Barbieri A, Pinto P, et al. Cerebrospinal fluid amyloid-β 42, total tau and phosphorylated tau are low in patients with normal pressure hydrocephalus: analogies and differences with Alzheimer’s disease. Vol. 60, J Alzheimers Dis. 2017. p. 183–200.
5.
Azman KF, Zakaria R. Recent Advances on the role of brain-derived neurotrophic factor (BDNF) in neurodegenerative diseases. Vol. 23, Int J Mol Sci. 2022.
6.
Ou ZA, Byrne LM, Rodrigues FB, Tortelli R, Johnson EB, Foiani MS, et al. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease. Vol. 11, Sci Rep. 2021.
7.
Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Vol. 202, Neurosci Lett. 1995. p. 17–20.
8.
Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Vol. 211, Neurosci Lett. 1996. p. 13–6.
9.
Li X, Miyajima M, Jiang C, Arai H. Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus. Vol. 413, Neurosci Lett. 2007. p. 141–4.
10.
Tarkowski E, Tullberg M, Fredman P, Wikkelsö C. Normal pressure hydrocephalus triggers intrathecal production of TNF-alpha. Vol. 24, Neurobiol Aging. 2003. p. 707–14.
11.
Seppi D, Puthenparampil M, Federle L, Ruggero S, Toffanin E, Rinaldi F, et al. Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset. Vol. 270, J Neuroimmunol. 2014. p. 56–60.
12.
Nakajima M, Yamada S, Miyajima M. Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus. In: Endorsed by the Japanese Society of Normal Pressure Hydrocephalus.
13.
Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti LG, et al. A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. Vol. 5, Sci Rep. 2015.
Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, et al. Brain-derived neurotrophic factor in patients with Huntington’s disease. Vol. 6:e22966, PLoS One. 2011.
16.
Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington’s disease patients. Vol. 144, Am J Med Genet B Neuropsychiatr Genet. 2007. p. 574–7.
17.
Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. Vol. 41, J Psychiatr Res. 2007. p. 387–94.
18.
Angelucci F, Spalletta G, Iulio F, Ciaramella A, Salani F, Colantoni L, et al.
19.
Faria MC, Gonçalves GS, Rocha NP, Moraes EN, Bicalho MA, Gualberto Cintra MT, et al. Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. Vol. 53, J Psychiatr Res. 2014. p. 166–72.
20.
Lee JG, Shin BS, You YS, Kim JE, Yoon SW, Jeon DW, et al. Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Vol. 6, Psychiatry Investig. 2009. p. 299–305.
21.
Gezen-Ak D, Dursun E, Hanağası H, Bilgiç B, Lohman E, Araz ÖS, et al. HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment. Vol. 37, J Alzheimers Dis. 2013. p. 185–95.
22.
Ventriglia M, Zanardini R, Bonomini C, Zanetti O, Volpe D, Pasqualetti P, et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. Vol. 2013, Biomed Res Int. 2013.
23.
Coelho FG, Vital TM, Stein AM, Arantes FJ, Rueda AV, Camarini R, et al. Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer’s disease. Vol. 39, J Alzheimers Dis. 2014. p. 401–8.
24.
Fukumitsu H, Ohmiya M, Nitta A, Furukawa S, Mima T, Mori K. Aberrant expression of neurotrophic factors in the ventricular progenitor cells of infant congenitally hydrocephalic rats. Vol. 16, Childs Nerv Syst. 2000. p. 516–21.
25.
Pláteník J, Fišar Z, Buchal R, Jirák R, Kitzlerová E, Zvěřová M, et al. CREB, and BDNF in peripheral blood of patients with Alzheimer’s disease and depression. Vol. 50, Prog Neuropsychopharmacol Biol Psychiatry. 2014. p. 83–93.
26.
Weinstein G, Preis B, AS K, B C, TC S, C R, et al. Clinical and environmental correlates of serum BDNF: A descriptive study with plausible implications for AD research. Vol. 14, Curr Alzheimer Res. 2017. p. 722–30.
27.
Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer’s disease patients. Vol. 27, Neurol Sci. 2006. p. 33–9.
28.
Sosvorova L, Kanceva R, Vcelak J, Kancheva L, Mohapl M, Starka L, et al. The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus. Vol. 36, Neuro Endocrinol Lett. 2015. p. 564–71.
29.
Killer M, Arthur A, Al-Schameri AR, Barr J, Elbert D, Ladurner G, et al. Cytokine and growth factor concentration in cerebrospinal fluid from patients with hydrocephalus following endovascular embolization of unruptured aneurysms in comparison with other types of hydrocephalus. Vol. 35, Neurochem Res. 2010. p. 1652–8.
30.
Yardan T, Erenler AK, Baydin A, Aydin K, Cokluk C. Usefulness of S100B protein in neurological disorders. Vol. 61, J Pak Med Assoc. 2011. p. 276–81.
31.
Bellaver B, Ferrari-Souza JP, Ros L, Carter SF, Rodriguez-Vieitez E, Nordberg A, et al. Astrocyte biomarkers in Alzheimer disease: a systematic review and meta-analysis. Vol. 5, Neurology. 2021.
32.
Levada OA, Traïlin AV. Serum level of S100B as a marker of progression of vascular mild cognitive impairment into subcortical vascular dementia and therapy effectiveness. Lik Sprava (Ukrainian. 2012. p. 53–9.
33.
Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Vol. 235, Neurosci Lett. 1997. p. 5–8.
34.
Katayama T, Sawada J, Takahashi K, Yahara O, Hasebe N. Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Vol. 13, Alzheimers Res Ther. 2021.
35.
Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Vol. 15, Lancet Neurol. 2016. p. 673–84.
36.
Nooijen PT, Schoonderwaldt HC, Wevers RA, Hommes OR, Lamers KJ. Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia. Vol. 8, Dement Geriatr Cogn Disord. 1997. p. 169–73.
37.
Virhammar J, Laurell K, Cesarini KG, Larsson EM. The callosal angle measured on MRI as a predictor of outcome in idiopathic normal-pressure hydrocephalus. Vol. 120, J Neurosurg. 2014. p. 178–84.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
